Business Context and Reporting Period
This Form 6-K filing by GSK plc (the "Company") reports a transaction in its own shares conducted on October 17, 2025. The filing was submitted on October 20, 2025. The Company acted through BNP Paribas SA as the broker to purchase ordinary shares of 31½ pence each as part of an existing buyback programme established under a non-discretionary agreement announced on September 30, 2025.
Key Financial Metrics and Transaction Details
The filing details a specific share repurchase event rather than general financial performance metrics such as revenue or profit.
- Shares Purchased: 414,000 ordinary shares.
- Price Range: Lowest price paid was 1,597.50p; highest price paid was 1,620.50p.
- Volume-Weighted Average Price (VWAP): 1,608.93p.
- Trading Venues: Purchases were executed across BATE, CHIX, and XLON.
- Treasury Share Holdings: Following this purchase, the Company holds 252,108,344 ordinary shares in treasury.
- Shares in Issue: 4,063,308,575 ordinary shares (excluding Treasury shares).
- Voting Rights: Treasury shares represent 6.20% of the total voting rights.
Material Changes and Programme Progress
Since the commencement of the current buyback phase on September 30, 2025, the Company has purchased a total of 4,643,500 ordinary shares. The transaction reported herein represents the latest activity within this ongoing programme. No other material changes to the Company's financial position or operations are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains a standard cautionary statement regarding forward-looking statements. GSK notes that any projections are subject to risks and uncertainties that may cause actual results to differ materially. Specific risk factors are referenced in the Company's Annual Report on Form 20-F for 2024 and its Q2 Results for 2025. No new guidance or specific management commentary regarding future financial performance is provided in this document.
Investor Verification Checklist
- Verify the total number of treasury shares held (252,108,344) against the latest capital structure disclosures.
- Confirm the percentage of voting rights attributable to treasury shares (6.20%) for disclosure threshold calculations under FCA rules.
- Review the cumulative buyback volume since September 30, 2025 (4,643,500 shares) to assess the remaining capacity under the current programme.
- Check the specific trading venues (BATE, CHIX, XLON) for execution quality analysis if required.